Assessing Pre-Commercial Value: Refractory Metastatic Colorectal Cancer (mCRC) Monoclonal Antibody

Assessing Pre-Commercial Value: Refractory Metastatic Colorectal Cancer (mCRC) Monoclonal Antibody

Metastatic Colorectal Cancer (mCRC) is the most advanced stage of colorectal cancer and represents around 20% of newly diagnosed patients.

The complexity of treatment algorithms increases at advanced stages of a disease, making it more challenging for newcomers to assess their target patient pool and estimate future revenues.

Cutting through the complexity and assessing a compound’s true market value is critical to making informed decisions, working with investors and CMOs, and ultimately shepherding the right investments to market to make the biggest impact for patients.

Read on to see Alira Health’s approach to pre-commercial value assessments with a refractory mCRC Monoclonal Antibody.

Pre-commercial value assessment of mCRC

For more information, or to receive a PDF download of this infographic, please contact Aude Ouensanga.